Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL943752 | 0.97 | SOS1 (0.31) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL31119586 | 0.97 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL700790 | 0.97 | SOS1 (0.33) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL994317 | 0.95 | SOS1 (0.32) | SOS1SOS2 | |
| SCHEMBL4716696 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL14938863 | 0.90 | — | — | |
| SCHEMBL16878030 | 0.87 | ALDH1A1 (0.38) | SOS1SOS2 | |
| SCHEMBL20842255 | 0.87 | CXCR4 (0.32) | SOS1SOS2 | |
| SCHEMBL336284 | 0.86 | — | — | |
| SCHEMBL16877823 | 0.85 | ALDH1A1 (0.30) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574134-A | Preparation method of treasipril and salt thereof | 济南圣泉集团股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-118666763-B | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118666763-B | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118666763-B | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118666763-A | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118666763-A | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118666763-A | Preparation method of 1, 4-diazaspiro [5.5] undecane-3-ketone | 常州优凯美医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118344298-A | Continuous preparation method of trealsil key intermediate | 南京威凯尔生物医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118344298-A | Continuous preparation method of trealsil key intermediate | 南京威凯尔生物医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117903147-A | Preparation method of treasipril and intermediate thereof | 沈阳药科大学 | 2024-04-19 | — | — | CN | disclosed |
| US-6861425-B2 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-0638073-B1 | 1-PIPERAZINO-1,2-DIHYDROINDENE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2000-06-21 | — | — | EP | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | SOS1 566/4885SOS2 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.